Table 2.
Accuracy of diagnostic panels for advanced liver fibrosis
| Reference | Biomarkers | N | AUROC | Cutoff value | Se (%) | Sp (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|---|---|
| Angulo [61] |
age≥45 years, obesity (BMI>31.1 for male, |
144 |
n/a |
n/a |
n/a |
n/a |
n/a |
n/a |
| |
>32.3 for female), diabetes, AAR>1 |
|
|
|
|
|
|
|
| Ratziu [62] |
BAAT score |
93 |
0.84 |
0 |
100 |
11 |
33 |
100 |
| |
(BMI≥28 kg/m2, age≥50 years, ALT≥2xULN, |
|
|
1 |
100 |
47 |
45 |
100 |
| |
triglycerides≥1.7 mmol/L) |
|
|
2 |
71 |
80 |
61 |
86 |
| |
|
|
|
3 |
14 |
100 |
100 |
73 |
| |
|
|
|
4 |
0 |
100 |
0 |
70 |
| Rosenberg |
Original European Liver Fibrosis panel |
61 |
0.87 |
0.375 |
89 |
96 |
80 |
98 |
| [63] |
(age, HA, TIMP1, PIIINP) |
|
|
0.462 |
78 |
98 |
87 |
96 |
| Guha [64] |
Enhanced Liver Fibrosis panel |
192 |
0.90 |
0.3576 |
80 |
90 |
71 |
94 |
| |
(HA, TIMP1, PIIINP) |
|
|
|
|
|
|
|
| Gholam [51] |
ALT, HbA1C |
97 |
0.90 |
6.6 |
83 |
82 |
n/a |
n/a |
| Ratziu [65] |
FibroTest |
267 |
0.81 |
0.3 |
77 |
77 |
54 |
90 |
| |
(α2 macroglobulin, haptoglobin, GGT, |
|
|
0.7 |
15 |
98 |
73 |
76 |
| |
Total bilirubin, apolipoprotein A1) |
|
|
|
|
|
|
|
| Angulo [66] |
NAFLD Fibrosis Score |
733 |
0.84 |
<−1.455† |
82 |
77 |
56 |
93 |
| |
(age, hyperglycemia, BMI, platelet count, |
|
|
>0.676† |
51 |
98 |
90 |
85 |
| |
albumin, AAR) |
|
|
<−1.455¥ |
77 |
71 |
52 |
88 |
| |
|
|
|
>0.676¥ |
43 |
96 |
82 |
80 |
| Harrison [67] |
BARD score |
827 |
0.81 |
2-4 |
|
|
43 |
96 |
| |
(BMI≥28 kg/m2, AAR≥0.8, diabetes) |
|
|
|
|
|
|
|
| Cales [68] |
Fibrometer NAFLD |
235 |
0.943 |
|
78.5 |
95.9 |
87.9 |
92.1 |
| |
(glucose, AST, ferritin, ALT, body weight, |
|
|
|
|
|
|
|
| |
age) |
|
|
|
|
|
|
|
| Shah [69] |
FIB4 index |
541 |
0.802 |
<1.30 |
74 |
71 |
43 |
90 |
| |
(age, ALT, AST, platelet count) |
|
|
>2.67 |
33 |
98 |
80 |
83 |
| Sumida [59] |
NAFIC score |
619 |
0.834 |
0 |
95 |
33 |
32 |
96 |
| |
[serum ferritin (≥200 ng/mL for female, |
|
|
2-4 |
84 |
74 |
52 |
93 |
| |
≥300 ng/mL for male), fasting insulin≥10 |
|
|
|
|
|
|
|
| |
μU/mL, type IV collagen 7S≥5 ng/mL] |
|
|
|
|
|
|
|
| Younossi [60] |
NAFLD Diagnostic Panel |
79 |
0.80 |
0.2188 |
90.91 |
43.59 |
57.7 |
85 |
| |
(diabetes, gender, BMI, triglycerides, |
|
|
0.4242 |
60.61 |
71.79 |
64.5 |
68.3 |
| apoptotic and necrotic CK18 fragments) | 0.5689 | 51.52 | 89.74 | 81 | 68.6 |
AUROC, area under receiver operator characteristic curve; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; AAR, AST/ALT ratio; HA, hyaluronic acid; GGT, gamma-glutamyl transpeptidase; TIMP1, tissue inhibitor of metalloproteinase 1; PIIINP, amino-terminal propeptide of type III collagen; ULN, upper limit of normal; n/a, not available.
†Estimation group; ¥Validation group.